Lineage Cell Therapeutics Inc (AMEX:LCTX) traded at $0.50 at close of the session on Tuesday, December 17 and made a downward move of -0.62% on its previous day’s price.
Looking at the stock we see that its previous close was $0.50 and the beta (5Y monthly) reads 1.282 with the day’s price range being $0.481 – $0.5231. In terms of its 52-week price range, LCTX has a high of $1.61 and a low of $0.49. The company’s stock has lost about -42.52% over that past 30 days.
Lineage Cell Therapeutics Inc has a market cap of $109.52 million and is expected to release its quarterly earnings report in January.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 1.62M, with a low of 840k and a high of 3.78M. The median projection represents growth adding up to -23.46% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 8.25M, or -7.73% down from figures reported last year.
On the other hand, looking at the outlook for the LCTX stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell.
Looking further, we note the current price level is -14.51% off its SMA20 and -34.34% from its 50-day simple moving average. The RSI (14) is pointing at 32.53 while the volatility over the past week is 10.69% and jumps to 11.14% over the past one month. The beta value is 1.17, while the average true range (ATR) is currently pointing at 0.06.
Coming back to Lineage Cell Therapeutics Inc (AMEX:LCTX), we note that the average 3-month trading volume was 1.62 million, while that of the preceding 10-day period stands at 2.64 million. Current shares outstanding are 220.42 million.
The insiders hold 0.66% of the company’s shares while institutions hold 43.57%. The data shows that short shares as of 2024-10-31, stood at 15.94 million at a short ratio of 35.21. This represents a 1089.00 short interest in shares outstanding on 2024-10-31. Shares short rose in October from the previous month at 15.22 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -54.41% down in year-to-date price movement.
